Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 92

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 92
---
itive practices to raise prices for two lucrative drugs. 6 Comprehensive HRDD that includes access to medicines would enable AbbVie to identify human rights impacts of its own operations, such as harmful pricing practices and shortcomings in access programs. According to Deloitte, it is not possible for a company to “really commit to respecting and promoting human rights without having full transparency of its human rights impacts.” 7Publicly releasing the resulting HRIA would allow shareholders to assess AbbVie’s human rights performance. _____________________________ 1www.ohchr.org/en/instruments-mechanisms/instruments/international-covenant-economic-social-and-cultural-rights; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605313/ 2www.un.org/en/development/desa/population/migration/generalassembly/docs/globalcompact/A_RES_70_1_E.pdf 3https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/our-commitment-to-human-rights.pdf, at 2 4https://www.abbvie.com/content/dam/abbvie-com2/pdfs/about/our-commitment-to-human-rights.pdf, at 3 5 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01545-9/fulltext 6https://www.nbcnews.com/politics/congress/pharmaceutical-company-abbvie-inflated-prices-two-major-drugs-house-oversight-n1267591; https://www.i-mak.org/wp-content/uploads/2020/10/i-mak.humira.report.3.final-REVISED-2020-10-06.pdf 7 https://www.deloitte.com/global/en/services/risk-advisory/blogs/human-rights-due-diligence-in-the-modern-era.html Board of Directors Statement in Opposition to the Stockholder Proposal to Conduct a Human Rights Assessment The Board of Directors recommends that stockholders vote AGAINSTthis proposal. 80 | 2025 Proxy Statement

| ​ | STOCKHOLDER PROPOSALS |

Requiring the company to conduct a human rights impact assessment covering AbbVie’s operations, activities, business relationships, and products, including access to medicines, would be repetitive of our existing efforts and unnecessary. AbbVie already prioritizes human rights and has thoroughly integrated human rights diligence and practices into its business—whether it be in our supply chain, our own workers, or in the delivery of our medicines. At AbbVie